Long-term Safety, Tolerability and Efficacy of BAF312 Giv... | NCT01185821 | Trialant
NCT01185821
Sponsor
Novartis Pharmaceuticals
Status
Completed
Last Update Posted
Mar 27, 2018Actual
Enrollment
185Actual
Phase
Phase 2
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
BAF312
Countries
United States
Canada
Finland
Germany
Hungary
Italy
Norway
Poland
Russia
Spain
Switzerland
Turkey (Türkiye)
Protocol Section
Identification Module
NCT ID
NCT01185821
Obsolete or Duplicate NCT IDs
Not provided
Organization Study
CBAF312A2201E1
Secondary IDs
ID
Type
Description
Link
2009-014392-51
EudraCT Number
Brief Title
Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis
Official Title
A Dose Blinded Extension Study to the CBAF312A2201 Study to Evaluate Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Acronym
Not provided
Organization
NovartisINDUSTRY
Status Module
Record Verification Date
Feb 2018
Overall Recruitment Status or Expanded Access Status
Completed
Last Known Status
Not provided
Delayed Posting
Not provided
Why Stopped
Not provided
Expanded Access Info
No
Start Date
Aug 30, 2010Actual
Primary Completion Date
Oct 10, 2016Actual
Completion Date
Oct 10, 2016Actual
First Submitted Date
Aug 19, 2010
First Submission Date that Met QC Criteria
Aug 19, 2010
First Posted Date
Aug 20, 2010Estimated
Results Waived
Not provided
Results First Submitted Date
Oct 10, 2017
Results First Submitted that Met QC Criteria
Nov 12, 2017
Results First Posted Date
Dec 12, 2017Actual
Certification/Extension (aka Delayed Results) First Submitted Date
Not provided
Certification/Extension First Submitted that Passed QC Review
Not provided
Certification/Extension First Posted Date
Not provided
Last Update Submitted Date
Feb 27, 2018
Last Update Posted Date
Mar 27, 2018Actual
Sponsor/Collaborators Module
Responsible Party, by Official Title
Sponsor
Lead Sponsor
Novartis PharmaceuticalsINDUSTRY
Collaborators
Not provided
Oversight Module
Has Data Monitoring Committee (DMC)
Yes
Is FDA Regulated Drug
Yes
Is FDA Regulated Device
No
Is Unapproved Device
Not provided
Pediatric Postmarket Surveillance of a Device Product
Not provided
Product Exported from US
Not provided
FDAAA801 Violation
Not provided
Description Module
Brief Summary
This study consisted of a two year dose blinded phase during which patients received one of five doses of siponimod (10, 2, 1.25, 0.5 or 0.25mg) following which patients were switched to open label treatment with siponimod 2mg for approximately a further 3 years. It will provide data on long term safety, tolerability and efficacy of siponimod in the RRMS patient population
Detailed Description
This study was prematurely discontinued after approximately 5 years. The decision to prematurely discontinue the study was not taken due to safety-related concerns, rather due to a decision to focus the development of siponimod in MS on a different population.
Conditions Module
Conditions
Relapsing Remitting Multiple Sclerosis
Keywords
BAF312
siponimod
Multiple Sclerosis
Relapsing remitting Multiple Sclerosis
Demyelinating Autoimmune Diseases
MS
RRMS
inflammatory disease
Design Module
Study Type
Interventional
Number of References to an Expanded Access Study
Not provided
Expanded Access Types
Not provided
Patient Registry
Not provided
Target Follow-Up Duration
Not provided
Phases
Phase 2
Interventional Study Design
Allocation
Biospecimen
No data available
No data is available for this block.
Enrollment
185Actual
Arms/Interventions Module
Arm Groups
Label
Type
Description
Intervention Names
BAF312 10 mg/2 mg
Experimental
10 mg dose in Double Blind Phase and 2 mg in Open Label Phase
Drug: BAF312
BAF312 2 mg/2 mg
Experimental
2 mg dose in Double Blind Phase and 2 mg in Open Label Phase
Drug: BAF312
BAF312 1.25 mg/2 mg
Experimental
1.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase
Drug: BAF312
BAF312 .5 mg/2 mg
Experimental
.5 mg dose in Double Blind Phase and 2 mg in Open Label Phase
Drug: BAF312
BAF312 .25 mg/2 mg
Experimental
.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase
Drug: BAF312
Interventions
Name
Type
Description
Arm Group Labels
Other Names
BAF312
Drug
BAF312 was supplied in film-coated tablets in strengths of 5, 4 ,2, 1, .5 and .25 mg. The actual doses taken were 10, 2, 1.25, .5 and .25 mg taken orally once a day.
Outcomes Module
Primary Outcomes
Measure
Description
Time Frame
Total Number of Adverse Events During Evaluation of Long Term Safety and Tolerability of BAF312A in Extension Study.
Refer to adverse events for complete listing of serious adverse events and other adverse events. Adverse events of interest were presented in separate tables. There were no reports of macular edema.
Baseline up to approximately 5 years
Number of Participants With Cardiac Conduction Abnormalities During the Titration Phase of the Study (Without Washout)
Number of patients with abnormal ECG conduction findings during dose-blinded titration at any visit post-dose, by type of abnormality and treatment (Extension Set). Number analyzed represent participants who had ECG results. Washout was defined as not being on treatment drug between Core and Extension for >7 days. Abbreviation: Con=conduction, IVCD=intraventricular conduction defect , WPW=Wolff-Parkinson-White syndrome
Baseline Extension up to day 10
Number of Participants With Cardiac Conduction-IVCD Abnormality During the Titration Phase of the Study (With Washout)
Number of patients with abnormal ECG conduction findings during dose-blinded titration at any visit post-dose, by type of abnormality and treatment (Extension Set). Number analyzed represent participants who had ECG results. Washout was defined as not being on treatment drug between Core and Extension for >7 days. Abbreviations: washout = WO, Con=conduction
Baseline Extension up to day 10
Number of Participants With Changes in Blood Pressure for Overall Extension Study. (Extension Analysis Set)
Sitting blood pressure was measured in triplicate. The categories of notably low and high values and changes are presented for systolic (SBP) and diastolic (DBP). Multiple occurrences for a patient are counted as one occurrence in this table.
Baseline Extension up to approximately 5 years
Number of Participants With Viral Infections of Interest Greater or Equal to 5% in Any Dose Group (Extension Set)
Secondary Outcomes
Measure
Description
Time Frame
Number of Relapses in One Year - Annualized Relapse Rates for Overall Extension Study (ARR) (Extension Set)
Group level ARR (raw) is calculated as the total number of relapses for all the patients in the treatment group divided by the total number of days on study for all patients in the group and multiplied by 365.25 to obtain the annual rate.
Model estimates are based on a negative binomial regression model, adjusted for treatment group, age, baseline EDSS, baseline number of Gd-enhanced T1 lesions and number of relapses in previous 2 years as covariates, with log(time on study in years) as the offset variable, using the log link.
Other Outcomes
Not provided
Eligibility Module
Eligibility Criteria
Inclusion Criteria:
Patients completed the core study BAF312A2201
Written informed consent provided before any assessment of the extension study
Female patients at risk of becoming pregnant must have a negative pregnancy test and use simultaneously two forms of effective contraception
Exclusion Criteria:
Newly diagnosed systemic disease other than MS (which may require immunosuppressive treatment)
Malignancies, diabetes, significant cardiovascular and pulmonary diseases and conditions
Kappos L, Li DK, Stuve O, Hartung HP, Freedman MS, Hemmer B, Rieckmann P, Montalban X, Ziemssen T, Hunter B, Arnould S, Wallstrom E, Selmaj K. Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis: Dose-Blinded, Randomized Extension of the Phase 2 BOLD Study. JAMA Neurol. 2016 Sep 1;73(9):1089-98. doi: 10.1001/jamaneurol.2016.1451.
See Also Links
Not provided
Available IPD Information
Not provided
IPD Sharing Statement Module
No data available
No data is available for this block.
Results Section
Participant Flow Module
Pre-assignment Details
During the double blind phase of the extension study patients received the same dose from the Core study. Placebo patients from Core Period 1 were randomized to 0.5, 2 or 10mg, those from Period 2 were randomized to 0.25 or 1.25 mg. All patients received 2mg in Open Label phase (.5 and .25mg were titrated up to 2mg)
Recruitment Details
All patients enrolled in the Extension study had completed the Core study. All patients underwent a 10 day titration at the start of the dose blinded phase of the study
Type of Units Analyzed
Not provided
Arm/Group Information
ID
Title
Description
FG000
BAF312 10 mg/2 mg
10 mg dose in Double Blind Phase and 2 mg in Open Label Phase
FG001
BAF312 2 mg/2 mg
2 mg dose in Double Blind Phase and 2 mg in Open Label Phase
Periods
Title
Milestones
Reasons Not Completed
Overall Study
Type
Comment
Milestone Data
STARTED
Baseline Characteristics Module
Baseline Analysis Population Description
Outcome Measures Module
Outcome Measures
Adverse Events Module
Frequency Threshold
3.999
More Info Module
Limitations and Caveats
Not provided
Annotation Section
No data available
No data is available for this block.
Document Section
No data available
No data is available for this block.
Derived Section
Miscellaneous Info Module
Version Holder
Jul 10, 2026
Removed Countries
Not provided
Submission Tracking
No data available
No data is available for this block.
Condition Browse Module
MeSH Terms
Intervention Browse Module
MeSH Terms
Randomized
Intervention Model
Parallel Assignment
Intervention Model Description
This extension study was originally set up as a 2 year dose-blinded extension study to maintain blinding of ongoing Core study. Study was later amended to include a subsequent Open-Label treatment phase after Core study was unblinded. During the Dose-Blinded phase of the extension study patients received the same dose from the Core study. Patients who received placebo in Period 1 during the Core Study were equally randomized to 1 of the 3 active doses of siponimod used during Period 1 (0.5, 2.0, or 10 mg) and patients who received placebo in Period 2 were equally randomized to 1 of the 2 active doses of siponimod used during Period 2 (0.25 mg or 1.25 mg).
Primary Purpose
Treatment
Observational Model
Not provided
Time Perspective
Not provided
Masking Info
Masking
Quadruple
Masking Description
Masking continued during the double blind period of extension only.
Most infections were clinical diagnoses and were not confirmed by microbiology / virologic investigations. A patient with multiple occurrences of an infection for a preferred term is counted only once in each specific category.
Events identified as infections by the Investigator and defined as an AE with onset on or after the first dose of Extension Study drug up to and including 30 days after the date of the last dose
Baseline Extension up to approximately 5 years
Number of Participants With Dermatologic Alterations - Basal Cell Carcinoma (Extension Set)
Baseline Extension up to approximately 5 years
Baseline extension up to approximately 5 years
Percentage of Participants Free of Magnetic Resonance Imaging (MRI) Identified Disease Activity at Any Scan During Extension Study (Extension Set)
Free of MRI disease activity is defined as free of Gadolinium enhanced T1 lesions at any scan; free of new or enlarging T2 lesions at any scan: free of both gadolinium enhanced T1 lesions and new or enlarging T2 lesions at any scan. Number of patients analyzed = patients with at least one MRI scan during the specified time period. New lesions at a specific visit are assessed relative to the previous scheduled visit scan.
No imputation of missing scans is performed. As a result missing scans can lead to an overestimation of the proportion of patients free of a specific MRI activity.
Baseline Extension up to approximately 5 years
Percentage of Participants Free of Confirmed Disability Progression in Extension Study (Extension Set)
Six-month disability progression was defined relative to extension baseline EDSS score: 1.5 point increase in patients with baseline EDSS score of 0, 1.0 increase in patients with baseline EDSS score of between 0.5 to 5.0, inclusive and 0.5 increase in patients with baseline EDSS score of ≥ 5.5. The criteria for 6-month disability progression included detection of onset of progression and confirmation of progression for a period of at least 6 months.
1.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase
FG003
BAF312 .5 mg/2 mg
.5 mg dose in Double Blind Phase and 2 mg in Open Label Phase
FG004
BAF312 .25 mg/2 mg
.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase
FG00033 subjects
FG00129 subjects
FG00243 subjects
FG00329 subjects
FG00450 subjects
Patients With Washout
FG00033 subjects
FG00129 subjects
FG00239 subjects
FG00329 subjects
FG00433 subjects
Patients Without Washout
FG0000 subjects
FG0010 subjects
FG0024 subjects
FG0030 subjects
FG00417 subjects
Patients on Placebo in Core
FG0008 subjects
FG0017 subjects
FG0029 subjects
FG0038 subjects
FG0042 subjects
COMPLETED
FG00026 subjects
FG00120 subjects
FG00233 subjects
FG00323 subjects
FG00426 subjects
NOT COMPLETED
FG0007 subjects
FG0019 subjects
FG00210 subjects
FG0036 subjects
FG00424 subjects
Type
Comment
Reasons
Abnormal laboratory value(s)
FG0001 subjects
FG0012 subjects
FG0021 subjects
FG0030 subjects
FG0040 subjects
Protocol Violation
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0031 subjects
FG004
Abnormal test procedure result
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
Death
FG0000 subjects
FG0011 subjects
FG0020 subjects
FG0030 subjects
FG004
Condition no longer required study drug
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
Adverse Event
FG0002 subjects
FG0013 subjects
FG0021 subjects
FG0032 subjects
FG004
Lack of Efficacy
FG0000 subjects
FG0010 subjects
FG0023 subjects
FG0030 subjects
FG004
Withdrawal by Subject
FG0003 subjects
FG0012 subjects
FG0022 subjects
FG0031 subjects
FG004
Lost to Follow-up
FG0001 subjects
FG0011 subjects
FG0022 subjects
FG0031 subjects
FG004
Administrative problems
FG0000 subjects
FG0010 subjects
FG0021 subjects
FG0031 subjects
FG004
The Extension set consisted of all patients who received at least one dose of Extension study drug who do not have a major protocol deviation.
Type of Units Analyzed
Not provided
Arm/Group Information
ID
Title
Description
BG000
BAF312 10 mg/2 mg
10 mg dose in Double Blind Phase and 2 mg in Open Label Phase
BG001
BAF312 2 mg/2 mg
2 mg dose in Double Blind Phase and 2 mg in Open Label Phase
BG002
BAF312 1.25 mg/2 mg
1.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase
BG003
BAF312 .5 mg/2 mg
.5 mg dose in Double Blind Phase and 2 mg in Open Label Phase
BG004
BAF312 .25 mg/2 mg
.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase
BG005
Total
Total of all reporting groups
Denominators
Units
Counts
Participants
BG00033
BG00129
BG00243
BG00329
BG00450
BG005184
Baseline Measures
Title
Description
Population Description
Parameter Type
Dispersion Type
Unit of Measure
Calculate Percentage
Denominator Units Selected
Denominators
Classes
Age, Continuous
Mean
Standard Deviation
years
Title
Denominators
Categories
Title
Measurements
BG00036.8± 9.09
BG00135.1± 9.16
BG00234.0± 7.57
BG003
Sex: Female, Male
Count of Participants
Participants
Title
Denominators
Categories
Title
Measurements
Female
BG00021
BG00118
BG002
Expanded disability status scale (EDSS)
Disability progression was assessed based on the EDSS scores ranging from 0 (normal) to 10 (death due to MS)
Mean
Standard Deviation
units on a scale
Title
Denominators
Categories
Title
Measurements
BG0002.03± 0.960
BG0012.19
Type
Title
Description
Population Description
Reporting Status
Anticipated Posting Date
Parameter Type
Dispersion Type
Unit of Measure
Calculate Percentage
Time Frame
Units Analyzed
Denominator Units Selected
Arm/Group Information
Denominators
Classes
Analyses
Primary
Total Number of Adverse Events During Evaluation of Long Term Safety and Tolerability of BAF312A in Extension Study.
Refer to adverse events for complete listing of serious adverse events and other adverse events. Adverse events of interest were presented in separate tables. There were no reports of macular edema.
Posted
Number
events
Baseline up to approximately 5 years
ID
Title
Description
OG000
BAF312 10 mg/2 mg
10 mg dose in Double Blind Phase and 2 mg in Open Label Phase
OG001
BAF312 2 mg/2 mg
2 mg dose in Double Blind Phase and 2 mg in Open Label Phase
OG002
BAF312 1.25 mg/2 mg
1.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase
OG003
BAF312 .5 mg/2 mg
.5 mg dose in Double Blind Phase and 2 mg in Open Label Phase
OG004
BAF312 .25 mg/2 mg
.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase
Units
Counts
Participants
OG00033
OG00129
OG00243
OG003
Title
Denominators
Categories
Serious adverse events
Title
Measurements
OG0004
OG0017
OG0026
OG003
Primary
Number of Participants With Cardiac Conduction Abnormalities During the Titration Phase of the Study (Without Washout)
Number of patients with abnormal ECG conduction findings during dose-blinded titration at any visit post-dose, by type of abnormality and treatment (Extension Set). Number analyzed represent participants who had ECG results. Washout was defined as not being on treatment drug between Core and Extension for >7 days. Abbreviation: Con=conduction, IVCD=intraventricular conduction defect , WPW=Wolff-Parkinson-White syndrome
Posted
Number
participants
Baseline Extension up to day 10
ID
Title
Description
OG000
BAF312 10 mg/2 mg
10 mg dose in Double Blind Phase and 2 mg in Open Label Phase
OG001
BAF312 2 mg/2 mg
2 mg dose in Double Blind Phase and 2 mg in Open Label Phase
OG002
BAF312 1.25 mg/2 mg
1.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase
OG003
BAF312 .5 mg/2 mg
.5 mg dose in Double Blind Phase and 2 mg in Open Label Phase
Primary
Number of Participants With Cardiac Conduction-IVCD Abnormality During the Titration Phase of the Study (With Washout)
Number of patients with abnormal ECG conduction findings during dose-blinded titration at any visit post-dose, by type of abnormality and treatment (Extension Set). Number analyzed represent participants who had ECG results. Washout was defined as not being on treatment drug between Core and Extension for >7 days. Abbreviations: washout = WO, Con=conduction
Posted
Number
participants
Baseline Extension up to day 10
ID
Title
Description
OG000
BAF312 .25 mg/2 mg
.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase
Units
Counts
Participants
OG000
Primary
Number of Participants With Changes in Blood Pressure for Overall Extension Study. (Extension Analysis Set)
Sitting blood pressure was measured in triplicate. The categories of notably low and high values and changes are presented for systolic (SBP) and diastolic (DBP). Multiple occurrences for a patient are counted as one occurrence in this table.
Posted
Number
participants
Baseline Extension up to approximately 5 years
ID
Title
Description
OG000
BAF312 10 mg/2 mg
10 mg dose in Double Blind Phase and 2 mg in Open Label Phase
OG001
BAF312 2 mg/2 mg
2 mg dose in Double Blind Phase and 2 mg in Open Label Phase
OG002
BAF312 1.25 mg/2 mg
1.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase
OG003
BAF312 .5 mg/2 mg
.5 mg dose in Double Blind Phase and 2 mg in Open Label Phase
OG004
BAF312 .25 mg/2 mg
Primary
Number of Participants With Viral Infections of Interest Greater or Equal to 5% in Any Dose Group (Extension Set)
Most infections were clinical diagnoses and were not confirmed by microbiology / virologic investigations. A patient with multiple occurrences of an infection for a preferred term is counted only once in each specific category.
Events identified as infections by the Investigator and defined as an AE with onset on or after the first dose of Extension Study drug up to and including 30 days after the date of the last dose
Posted
Number
participants
Baseline Extension up to approximately 5 years
ID
Title
Description
OG000
BAF312 10 mg/2 mg
10 mg dose in Double Blind Phase and 2 mg in Open Label Phase
OG001
BAF312 2 mg/2 mg
2 mg dose in Double Blind Phase and 2 mg in Open Label Phase
OG002
BAF312 1.25 mg/2 mg
1.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase
OG003
BAF312 .5 mg/2 mg
.5 mg dose in Double Blind Phase and 2 mg in Open Label Phase
Primary
Number of Participants With Dermatologic Alterations - Basal Cell Carcinoma (Extension Set)
Posted
Number
participants
Baseline Extension up to approximately 5 years
ID
Title
Description
OG000
BAF312 10 mg/2 mg
10 mg dose in Double Blind Phase and 2 mg in Open Label Phase
OG001
BAF312 2 mg/2 mg
2 mg dose in Double Blind Phase and 2 mg in Open Label Phase
OG002
BAF312 1.25 mg/2 mg
1.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase
OG003
BAF312 .5 mg/2 mg
.5 mg dose in Double Blind Phase and 2 mg in Open Label Phase
OG004
BAF312 .25 mg/2 mg
.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase
Secondary
Number of Relapses in One Year - Annualized Relapse Rates for Overall Extension Study (ARR) (Extension Set)
Group level ARR (raw) is calculated as the total number of relapses for all the patients in the treatment group divided by the total number of days on study for all patients in the group and multiplied by 365.25 to obtain the annual rate.
Model estimates are based on a negative binomial regression model, adjusted for treatment group, age, baseline EDSS, baseline number of Gd-enhanced T1 lesions and number of relapses in previous 2 years as covariates, with log(time on study in years) as the offset variable, using the log link.
Posted
Mean
95% Confidence Interval
Group level ARR
Baseline extension up to approximately 5 years
ID
Title
Description
OG000
BAF312 10 mg/2 mg
10 mg dose in Double Blind Phase and 2 mg in Open Label Phase
OG001
BAF312 2 mg/2 mg
2 mg dose in Double Blind Phase and 2 mg in Open Label Phase
OG002
BAF312 1.25 mg/2 mg
1.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase
OG003
BAF312 .5 mg/2 mg
Secondary
Percentage of Participants Free of Magnetic Resonance Imaging (MRI) Identified Disease Activity at Any Scan During Extension Study (Extension Set)
Free of MRI disease activity is defined as free of Gadolinium enhanced T1 lesions at any scan; free of new or enlarging T2 lesions at any scan: free of both gadolinium enhanced T1 lesions and new or enlarging T2 lesions at any scan. Number of patients analyzed = patients with at least one MRI scan during the specified time period. New lesions at a specific visit are assessed relative to the previous scheduled visit scan.
No imputation of missing scans is performed. As a result missing scans can lead to an overestimation of the proportion of patients free of a specific MRI activity.
Posted
Number
percentage of participants
Baseline Extension up to approximately 5 years
ID
Title
Description
OG000
BAF312 10 mg/2 mg
10 mg dose in Double Blind Phase and 2 mg in Open Label Phase
OG001
BAF312 2 mg/2 mg
2 mg dose in Double Blind Phase and 2 mg in Open Label Phase
OG002
BAF312 1.25 mg/2 mg
1.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase
OG003
Secondary
Percentage of Participants Free of Confirmed Disability Progression in Extension Study (Extension Set)
Six-month disability progression was defined relative to extension baseline EDSS score: 1.5 point increase in patients with baseline EDSS score of 0, 1.0 increase in patients with baseline EDSS score of between 0.5 to 5.0, inclusive and 0.5 increase in patients with baseline EDSS score of ≥ 5.5. The criteria for 6-month disability progression included detection of onset of progression and confirmation of progression for a period of at least 6 months.
Posted
Number
95% Confidence Interval
percentage of participants
Baseline Extension up to approximately 5 years
ID
Title
Description
OG000
BAF312 10 mg/2 mg
10 mg dose in Double Blind Phase and 2 mg in Open Label Phase
OG001
BAF312 2 mg/2 mg
2 mg dose in Double Blind Phase and 2 mg in Open Label Phase
OG002
BAF312 1.25 mg/2 mg
1.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase
OG003
BAF312 .5 mg/2 mg
.5 mg dose in Double Blind Phase and 2 mg in Open Label Phase
Time Frame
Adverse Events (AEs) are collected from First Patient First Visit (FPFV)until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit.
Description
Not provided
All-Cause Mortality Comment
Not provided
Arm/Groups
ID
Title
Description
Deaths (Affected)
Deaths (At Risk)
Serious Events (Affected)
Serious Events (At Risk)
Other Events (Affected)
Other Events (At Risk)
EG000
BAF312 10/2 mg
BAF312 10/2 mg
4
33
30
33
EG001
BAF312 2/2 mg
BAF312 2/2 mg
7
29
26
29
EG002
BAF312 1.25/2 mg
BAF312 1.25/2 mg
6
43
42
43
EG003
BAF312 0.5/2 mg
BAF312 0.5/2 mg
6
29
29
29
EG004
BAF312 0.25/2 mg
BAF312 0.25/2 mg
8
50
42
50
EG005
All Patients
All patients
31
184
169
184
Serious Adverse Events
Term
Organ System
Source Vocabulary
Assessment Type
Notes
Statistical Information
Splenic cyst
Blood and lymphatic system disorders
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0010 affected29 at risk
EG0020 affected43 at risk
EG0030 affected29 at risk
EG0041 affected50 at risk
EG0051 affected184 at risk
Otosclerosis
Ear and labyrinth disorders
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0010 affected29 at risk
EG0020 affected43 at risk
EG003
Glaucoma
Eye disorders
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0010 affected29 at risk
EG0021 affected43 at risk
EG003
Abdominal discomfort
Gastrointestinal disorders
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0011 affected29 at risk
EG0020 affected43 at risk
EG003
Gastritis
Gastrointestinal disorders
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0011 affected29 at risk
EG0020 affected43 at risk
EG003
Nausea
Gastrointestinal disorders
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0010 affected29 at risk
EG0020 affected43 at risk
EG003
Pancreatitis acute
Gastrointestinal disorders
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0010 affected29 at risk
EG0020 affected43 at risk
EG003
Vomiting
Gastrointestinal disorders
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0010 affected29 at risk
EG0020 affected43 at risk
EG003
Submandibular mass
General disorders
MedDRA (19.0)
Systematic Assessment
EG0001 affected33 at risk
EG0010 affected29 at risk
EG0020 affected43 at risk
EG003
Biliary dyskinesia
Hepatobiliary disorders
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0011 affected29 at risk
EG0020 affected43 at risk
EG003
Anaphylactic reaction
Immune system disorders
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0010 affected29 at risk
EG0020 affected43 at risk
EG003
Oral herpes
Infections and infestations
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0010 affected29 at risk
EG0020 affected43 at risk
EG003
Pyelonephritis
Infections and infestations
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0010 affected29 at risk
EG0020 affected43 at risk
EG003
Pyelonephritis acute
Infections and infestations
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0010 affected29 at risk
EG0020 affected43 at risk
EG003
Respiratory tract infection
Infections and infestations
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0010 affected29 at risk
EG0020 affected43 at risk
EG003
Upper respiratory tract infection
Infections and infestations
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0010 affected29 at risk
EG0020 affected43 at risk
EG003
Urinary tract infection
Infections and infestations
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0010 affected29 at risk
EG0020 affected43 at risk
EG003
Ankle fracture
Injury, poisoning and procedural complications
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0010 affected29 at risk
EG0020 affected43 at risk
EG003
Craniocerebral injury
Injury, poisoning and procedural complications
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0011 affected29 at risk
EG0020 affected43 at risk
EG003
Femur fracture
Injury, poisoning and procedural complications
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0011 affected29 at risk
EG0020 affected43 at risk
EG003
Tendon rupture
Injury, poisoning and procedural complications
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0010 affected29 at risk
EG0020 affected43 at risk
EG003
Smear cervix abnormal
Investigations
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0010 affected29 at risk
EG0020 affected43 at risk
EG003
Decreased appetite
Metabolism and nutrition disorders
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0010 affected29 at risk
EG0020 affected43 at risk
EG003
Basal cell carcinoma
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA (19.0)
Systematic Assessment
EG0001 affected33 at risk
EG0010 affected29 at risk
EG0021 affected43 at risk
EG003
Breast cancer
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0010 affected29 at risk
EG0021 affected43 at risk
EG003
Colon cancer metastatic
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0010 affected29 at risk
EG0020 affected43 at risk
EG003
Dysaesthesia
Nervous system disorders
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0010 affected29 at risk
EG0021 affected43 at risk
EG003
Generalised tonic-clonic seizure
Nervous system disorders
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0011 affected29 at risk
EG0020 affected43 at risk
EG003
Headache
Nervous system disorders
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0010 affected29 at risk
EG0020 affected43 at risk
EG003
Multiple sclerosis relapse
Nervous system disorders
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0010 affected29 at risk
EG0021 affected43 at risk
EG003
Sciatica
Nervous system disorders
MedDRA (19.0)
Systematic Assessment
EG0001 affected33 at risk
EG0010 affected29 at risk
EG0020 affected43 at risk
EG003
Seizure
Nervous system disorders
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0011 affected29 at risk
EG0020 affected43 at risk
EG003
Abortion
Pregnancy, puerperium and perinatal conditions
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0011 affected29 at risk
EG0020 affected43 at risk
EG003
Depression
Psychiatric disorders
MedDRA (19.0)
Systematic Assessment
EG0001 affected33 at risk
EG0010 affected29 at risk
EG0020 affected43 at risk
EG003
Drug abuse
Psychiatric disorders
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0010 affected29 at risk
EG0020 affected43 at risk
EG003
Mental disorder
Psychiatric disorders
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0010 affected29 at risk
EG0020 affected43 at risk
EG003
Stress urinary incontinence
Renal and urinary disorders
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0010 affected29 at risk
EG0021 affected43 at risk
EG003
Benign prostatic hyperplasia
Reproductive system and breast disorders
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0010 affected29 at risk
EG0020 affected43 at risk
EG003
Metrorrhagia
Reproductive system and breast disorders
MedDRA (19.0)
Systematic Assessment
EG0001 affected33 at risk
EG0010 affected29 at risk
EG0020 affected43 at risk
EG003
Uterine cervical metaplasia
Reproductive system and breast disorders
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0010 affected29 at risk
EG0020 affected43 at risk
EG003
Other Adverse Events
Term
Organ System
Source Vocabulary
Assessment Type
Notes
Statistical Information
Leukopenia
Blood and lymphatic system disorders
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0011 affected29 at risk
EG0020 affected43 at risk
EG0032 affected29 at risk
EG0040 affected50 at risk
EG0053 affected184 at risk
Lymphadenitis
Blood and lymphatic system disorders
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0010 affected29 at risk
EG0020 affected43 at risk
EG003
Lymphopenia
Blood and lymphatic system disorders
MedDRA (19.0)
Systematic Assessment
EG0006 affected33 at risk
EG0015 affected29 at risk
EG0024 affected43 at risk
EG003
Palpitations
Cardiac disorders
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0012 affected29 at risk
EG0020 affected43 at risk
EG003
Tachycardia
Cardiac disorders
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0010 affected29 at risk
EG0021 affected43 at risk
EG003
Ear pain
Ear and labyrinth disorders
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0011 affected29 at risk
EG0022 affected43 at risk
EG003
Tinnitus
Ear and labyrinth disorders
MedDRA (19.0)
Systematic Assessment
EG0001 affected33 at risk
EG0010 affected29 at risk
EG0020 affected43 at risk
EG003
Vertigo
Ear and labyrinth disorders
MedDRA (19.0)
Systematic Assessment
EG0004 affected33 at risk
EG0011 affected29 at risk
EG0023 affected43 at risk
EG003
Vertigo positional
Ear and labyrinth disorders
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0010 affected29 at risk
EG0020 affected43 at risk
EG003
Conjunctivitis
Eye disorders
MedDRA (19.0)
Systematic Assessment
EG0001 affected33 at risk
EG0010 affected29 at risk
EG0022 affected43 at risk
EG003
Eye pain
Eye disorders
MedDRA (19.0)
Systematic Assessment
EG0002 affected33 at risk
EG0010 affected29 at risk
EG0020 affected43 at risk
EG003
Iridocyclitis
Eye disorders
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0010 affected29 at risk
EG0022 affected43 at risk
EG003
Vision blurred
Eye disorders
MedDRA (19.0)
Systematic Assessment
EG0002 affected33 at risk
EG0010 affected29 at risk
EG0023 affected43 at risk
EG003
Abdominal pain
Gastrointestinal disorders
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0011 affected29 at risk
EG0022 affected43 at risk
EG003
Abdominal pain upper
Gastrointestinal disorders
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0011 affected29 at risk
EG0023 affected43 at risk
EG003
Aphthous ulcer
Gastrointestinal disorders
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0010 affected29 at risk
EG0021 affected43 at risk
EG003
Constipation
Gastrointestinal disorders
MedDRA (19.0)
Systematic Assessment
EG0001 affected33 at risk
EG0010 affected29 at risk
EG0020 affected43 at risk
EG003
Diarrhoea
Gastrointestinal disorders
MedDRA (19.0)
Systematic Assessment
EG0001 affected33 at risk
EG0012 affected29 at risk
EG0027 affected43 at risk
EG003
Dyspepsia
Gastrointestinal disorders
MedDRA (19.0)
Systematic Assessment
EG0001 affected33 at risk
EG0011 affected29 at risk
EG0021 affected43 at risk
EG003
Enteritis
Gastrointestinal disorders
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0012 affected29 at risk
EG0020 affected43 at risk
EG003
Gastritis
Gastrointestinal disorders
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0012 affected29 at risk
EG0020 affected43 at risk
EG003
Gastrooesophageal reflux disease
Gastrointestinal disorders
MedDRA (19.0)
Systematic Assessment
EG0001 affected33 at risk
EG0010 affected29 at risk
EG0021 affected43 at risk
EG003
Irritable bowel syndrome
Gastrointestinal disorders
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0010 affected29 at risk
EG0020 affected43 at risk
EG003
Nausea
Gastrointestinal disorders
MedDRA (19.0)
Systematic Assessment
EG0001 affected33 at risk
EG0010 affected29 at risk
EG0020 affected43 at risk
EG003
Toothache
Gastrointestinal disorders
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0012 affected29 at risk
EG0024 affected43 at risk
EG003
Vomiting
Gastrointestinal disorders
MedDRA (19.0)
Systematic Assessment
EG0001 affected33 at risk
EG0013 affected29 at risk
EG0020 affected43 at risk
EG003
Asthenia
General disorders
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0011 affected29 at risk
EG0022 affected43 at risk
EG003
Fatigue
General disorders
MedDRA (19.0)
Systematic Assessment
EG0001 affected33 at risk
EG0014 affected29 at risk
EG0025 affected43 at risk
EG003
Gait disturbance
General disorders
MedDRA (19.0)
Systematic Assessment
EG0003 affected33 at risk
EG0010 affected29 at risk
EG0020 affected43 at risk
EG003
Influenza like illness
General disorders
MedDRA (19.0)
Systematic Assessment
EG0001 affected33 at risk
EG0010 affected29 at risk
EG0022 affected43 at risk
EG003
Non-cardiac chest pain
General disorders
MedDRA (19.0)
Systematic Assessment
EG0003 affected33 at risk
EG0010 affected29 at risk
EG0021 affected43 at risk
EG003
Oedema peripheral
General disorders
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0012 affected29 at risk
EG0020 affected43 at risk
EG003
Pyrexia
General disorders
MedDRA (19.0)
Systematic Assessment
EG0002 affected33 at risk
EG0011 affected29 at risk
EG0024 affected43 at risk
EG003
Acute sinusitis
Infections and infestations
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0010 affected29 at risk
EG0020 affected43 at risk
EG003
Bronchitis
Infections and infestations
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0012 affected29 at risk
EG0025 affected43 at risk
EG003
Conjunctivitis
Infections and infestations
MedDRA (19.0)
Systematic Assessment
EG0002 affected33 at risk
EG0010 affected29 at risk
EG0021 affected43 at risk
EG003
Cystitis
Infections and infestations
MedDRA (19.0)
Systematic Assessment
EG0003 affected33 at risk
EG0011 affected29 at risk
EG0022 affected43 at risk
EG003
Fungal infection
Infections and infestations
MedDRA (19.0)
Systematic Assessment
EG0003 affected33 at risk
EG0011 affected29 at risk
EG0020 affected43 at risk
EG003
Fungal skin infection
Infections and infestations
MedDRA (19.0)
Systematic Assessment
EG0002 affected33 at risk
EG0010 affected29 at risk
EG0020 affected43 at risk
EG003
Gastroenteritis
Infections and infestations
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0012 affected29 at risk
EG0021 affected43 at risk
EG003
Gastroenteritis viral
Infections and infestations
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0010 affected29 at risk
EG0023 affected43 at risk
EG003
Herpes zoster
Infections and infestations
MedDRA (19.0)
Systematic Assessment
EG0005 affected33 at risk
EG0010 affected29 at risk
EG0023 affected43 at risk
EG003
Influenza
Infections and infestations
MedDRA (19.0)
Systematic Assessment
EG0004 affected33 at risk
EG0014 affected29 at risk
EG0025 affected43 at risk
EG003
Nasopharyngitis
Infections and infestations
MedDRA (19.0)
Systematic Assessment
EG00010 affected33 at risk
EG0018 affected29 at risk
EG00217 affected43 at risk
EG003
Onychomycosis
Infections and infestations
MedDRA (19.0)
Systematic Assessment
EG0001 affected33 at risk
EG0011 affected29 at risk
EG0020 affected43 at risk
EG003
Oral herpes
Infections and infestations
MedDRA (19.0)
Systematic Assessment
EG0005 affected33 at risk
EG0010 affected29 at risk
EG0024 affected43 at risk
EG003
Otitis media
Infections and infestations
MedDRA (19.0)
Systematic Assessment
EG0001 affected33 at risk
EG0011 affected29 at risk
EG0020 affected43 at risk
EG003
Pharyngitis
Infections and infestations
MedDRA (19.0)
Systematic Assessment
EG0001 affected33 at risk
EG0014 affected29 at risk
EG0023 affected43 at risk
EG003
Pneumonia
Infections and infestations
MedDRA (19.0)
Systematic Assessment
EG0001 affected33 at risk
EG0011 affected29 at risk
EG0020 affected43 at risk
EG003
Respiratory tract infection
Infections and infestations
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0011 affected29 at risk
EG0021 affected43 at risk
EG003
Rhinitis
Infections and infestations
MedDRA (19.0)
Systematic Assessment
EG0003 affected33 at risk
EG0012 affected29 at risk
EG0021 affected43 at risk
EG003
Sinusitis
Infections and infestations
MedDRA (19.0)
Systematic Assessment
EG0003 affected33 at risk
EG0012 affected29 at risk
EG0023 affected43 at risk
EG003
Subcutaneous abscess
Infections and infestations
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0012 affected29 at risk
EG0020 affected43 at risk
EG003
Tinea versicolour
Infections and infestations
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0012 affected29 at risk
EG0022 affected43 at risk
EG003
Tonsillitis
Infections and infestations
MedDRA (19.0)
Systematic Assessment
EG0001 affected33 at risk
EG0011 affected29 at risk
EG0025 affected43 at risk
EG003
Tooth infection
Infections and infestations
MedDRA (19.0)
Systematic Assessment
EG0001 affected33 at risk
EG0012 affected29 at risk
EG0021 affected43 at risk
EG003
Upper respiratory tract infection
Infections and infestations
MedDRA (19.0)
Systematic Assessment
EG0004 affected33 at risk
EG0016 affected29 at risk
EG0024 affected43 at risk
EG003
Urinary tract infection
Infections and infestations
MedDRA (19.0)
Systematic Assessment
EG0006 affected33 at risk
EG0014 affected29 at risk
EG0022 affected43 at risk
EG003
Vaginal infection
Infections and infestations
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0010 affected29 at risk
EG0021 affected43 at risk
EG003
Vulvovaginal candidiasis
Infections and infestations
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0010 affected29 at risk
EG0021 affected43 at risk
EG003
Contusion
Injury, poisoning and procedural complications
MedDRA (19.0)
Systematic Assessment
EG0002 affected33 at risk
EG0012 affected29 at risk
EG0020 affected43 at risk
EG003
Fall
Injury, poisoning and procedural complications
MedDRA (19.0)
Systematic Assessment
EG0003 affected33 at risk
EG0013 affected29 at risk
EG0020 affected43 at risk
EG003
Joint injury
Injury, poisoning and procedural complications
MedDRA (19.0)
Systematic Assessment
EG0001 affected33 at risk
EG0010 affected29 at risk
EG0022 affected43 at risk
EG003
Ligament sprain
Injury, poisoning and procedural complications
MedDRA (19.0)
Systematic Assessment
EG0002 affected33 at risk
EG0010 affected29 at risk
EG0022 affected43 at risk
EG003
Limb injury
Injury, poisoning and procedural complications
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0010 affected29 at risk
EG0020 affected43 at risk
EG003
Alanine aminotransferase increased
Investigations
MedDRA (19.0)
Systematic Assessment
EG0003 affected33 at risk
EG0015 affected29 at risk
EG0023 affected43 at risk
EG003
Blood bilirubin increased
Investigations
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0010 affected29 at risk
EG0020 affected43 at risk
EG003
Blood cholesterol increased
Investigations
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0010 affected29 at risk
EG0021 affected43 at risk
EG003
C-reactive protein increased
Investigations
MedDRA (19.0)
Systematic Assessment
EG0001 affected33 at risk
EG0011 affected29 at risk
EG0020 affected43 at risk
EG003
Gamma-glutamyltransferase increased
Investigations
MedDRA (19.0)
Systematic Assessment
EG0003 affected33 at risk
EG0013 affected29 at risk
EG0022 affected43 at risk
EG003
Hepatic enzyme increased
Investigations
MedDRA (19.0)
Systematic Assessment
EG0002 affected33 at risk
EG0011 affected29 at risk
EG0021 affected43 at risk
EG003
Lymphocyte count decreased
Investigations
MedDRA (19.0)
Systematic Assessment
EG0004 affected33 at risk
EG0012 affected29 at risk
EG0024 affected43 at risk
EG003
Hypercholesterolaemia
Metabolism and nutrition disorders
MedDRA (19.0)
Systematic Assessment
EG0002 affected33 at risk
EG0014 affected29 at risk
EG0022 affected43 at risk
EG003
Hypoglycaemia
Metabolism and nutrition disorders
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0010 affected29 at risk
EG0020 affected43 at risk
EG003
Arthralgia
Musculoskeletal and connective tissue disorders
MedDRA (19.0)
Systematic Assessment
EG0004 affected33 at risk
EG0013 affected29 at risk
EG0022 affected43 at risk
EG003
Back pain
Musculoskeletal and connective tissue disorders
MedDRA (19.0)
Systematic Assessment
EG0006 affected33 at risk
EG0012 affected29 at risk
EG0025 affected43 at risk
EG003
Intervertebral disc degeneration
Musculoskeletal and connective tissue disorders
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0010 affected29 at risk
EG0022 affected43 at risk
EG003
Joint swelling
Musculoskeletal and connective tissue disorders
MedDRA (19.0)
Systematic Assessment
EG0002 affected33 at risk
EG0010 affected29 at risk
EG0020 affected43 at risk
EG003
Muscle spasms
Musculoskeletal and connective tissue disorders
MedDRA (19.0)
Systematic Assessment
EG0001 affected33 at risk
EG0010 affected29 at risk
EG0022 affected43 at risk
EG003
Muscular weakness
Musculoskeletal and connective tissue disorders
MedDRA (19.0)
Systematic Assessment
EG0002 affected33 at risk
EG0010 affected29 at risk
EG0022 affected43 at risk
EG003
Musculoskeletal pain
Musculoskeletal and connective tissue disorders
MedDRA (19.0)
Systematic Assessment
EG0001 affected33 at risk
EG0012 affected29 at risk
EG0024 affected43 at risk
EG003
Myalgia
Musculoskeletal and connective tissue disorders
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0010 affected29 at risk
EG0021 affected43 at risk
EG003
Neck pain
Musculoskeletal and connective tissue disorders
MedDRA (19.0)
Systematic Assessment
EG0001 affected33 at risk
EG0012 affected29 at risk
EG0021 affected43 at risk
EG003
Pain in extremity
Musculoskeletal and connective tissue disorders
MedDRA (19.0)
Systematic Assessment
EG0002 affected33 at risk
EG0011 affected29 at risk
EG0020 affected43 at risk
EG003
Tendonitis
Musculoskeletal and connective tissue disorders
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0012 affected29 at risk
EG0020 affected43 at risk
EG003
Fibrous histiocytoma
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0011 affected29 at risk
EG0023 affected43 at risk
EG003
Melanocytic naevus
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA (19.0)
Systematic Assessment
EG0002 affected33 at risk
EG0011 affected29 at risk
EG0026 affected43 at risk
EG003
Seborrhoeic keratosis
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA (19.0)
Systematic Assessment
EG0002 affected33 at risk
EG0011 affected29 at risk
EG0020 affected43 at risk
EG003
Skin papilloma
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA (19.0)
Systematic Assessment
EG0002 affected33 at risk
EG0013 affected29 at risk
EG0021 affected43 at risk
EG003
Uterine leiomyoma
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA (19.0)
Systematic Assessment
EG0002 affected33 at risk
EG0010 affected29 at risk
EG0020 affected43 at risk
EG003
Burning sensation
Nervous system disorders
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0010 affected29 at risk
EG0021 affected43 at risk
EG003
Dizziness
Nervous system disorders
MedDRA (19.0)
Systematic Assessment
EG0001 affected33 at risk
EG0011 affected29 at risk
EG0021 affected43 at risk
EG003
Headache
Nervous system disorders
MedDRA (19.0)
Systematic Assessment
EG0009 affected33 at risk
EG0014 affected29 at risk
EG0029 affected43 at risk
EG003
Hypoaesthesia
Nervous system disorders
MedDRA (19.0)
Systematic Assessment
EG0001 affected33 at risk
EG0010 affected29 at risk
EG0020 affected43 at risk
EG003
Migraine
Nervous system disorders
MedDRA (19.0)
Systematic Assessment
EG0002 affected33 at risk
EG0010 affected29 at risk
EG0023 affected43 at risk
EG003
Muscle spasticity
Nervous system disorders
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0012 affected29 at risk
EG0020 affected43 at risk
EG003
Neuralgia
Nervous system disorders
MedDRA (19.0)
Systematic Assessment
EG0001 affected33 at risk
EG0010 affected29 at risk
EG0024 affected43 at risk
EG003
Paraesthesia
Nervous system disorders
MedDRA (19.0)
Systematic Assessment
EG0004 affected33 at risk
EG0010 affected29 at risk
EG0020 affected43 at risk
EG003
Anxiety
Psychiatric disorders
MedDRA (19.0)
Systematic Assessment
EG0003 affected33 at risk
EG0011 affected29 at risk
EG0021 affected43 at risk
EG003
Depression
Psychiatric disorders
MedDRA (19.0)
Systematic Assessment
EG0001 affected33 at risk
EG0011 affected29 at risk
EG0026 affected43 at risk
EG003
Insomnia
Psychiatric disorders
MedDRA (19.0)
Systematic Assessment
EG0001 affected33 at risk
EG0012 affected29 at risk
EG0028 affected43 at risk
EG003
Sleep disorder
Psychiatric disorders
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0011 affected29 at risk
EG0020 affected43 at risk
EG003
Bladder dysfunction
Renal and urinary disorders
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0010 affected29 at risk
EG0022 affected43 at risk
EG003
Micturition urgency
Renal and urinary disorders
MedDRA (19.0)
Systematic Assessment
EG0002 affected33 at risk
EG0011 affected29 at risk
EG0021 affected43 at risk
EG003
Nephrolithiasis
Renal and urinary disorders
MedDRA (19.0)
Systematic Assessment
EG0002 affected33 at risk
EG0012 affected29 at risk
EG0020 affected43 at risk
EG003
Urinary retention
Renal and urinary disorders
MedDRA (19.0)
Systematic Assessment
EG0001 affected33 at risk
EG0010 affected29 at risk
EG0020 affected43 at risk
EG003
Catarrh
Respiratory, thoracic and mediastinal disorders
MedDRA (19.0)
Systematic Assessment
EG0001 affected33 at risk
EG0010 affected29 at risk
EG0021 affected43 at risk
EG003
Cough
Respiratory, thoracic and mediastinal disorders
MedDRA (19.0)
Systematic Assessment
EG0003 affected33 at risk
EG0013 affected29 at risk
EG0023 affected43 at risk
EG003
Dyspnoea
Respiratory, thoracic and mediastinal disorders
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0010 affected29 at risk
EG0022 affected43 at risk
EG003
Epistaxis
Respiratory, thoracic and mediastinal disorders
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0010 affected29 at risk
EG0020 affected43 at risk
EG003
Oropharyngeal pain
Respiratory, thoracic and mediastinal disorders
MedDRA (19.0)
Systematic Assessment
EG0003 affected33 at risk
EG0011 affected29 at risk
EG0023 affected43 at risk
EG003
Rhinitis allergic
Respiratory, thoracic and mediastinal disorders
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0010 affected29 at risk
EG0022 affected43 at risk
EG003
Wheezing
Respiratory, thoracic and mediastinal disorders
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0010 affected29 at risk
EG0020 affected43 at risk
EG003
Actinic keratosis
Skin and subcutaneous tissue disorders
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0010 affected29 at risk
EG0022 affected43 at risk
EG003
Alopecia
Skin and subcutaneous tissue disorders
MedDRA (19.0)
Systematic Assessment
EG0002 affected33 at risk
EG0010 affected29 at risk
EG0022 affected43 at risk
EG003
Dermal cyst
Skin and subcutaneous tissue disorders
MedDRA (19.0)
Systematic Assessment
EG0001 affected33 at risk
EG0010 affected29 at risk
EG0020 affected43 at risk
EG003
Dermatitis
Skin and subcutaneous tissue disorders
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0010 affected29 at risk
EG0020 affected43 at risk
EG003
Dermatitis allergic
Skin and subcutaneous tissue disorders
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0010 affected29 at risk
EG0020 affected43 at risk
EG003
Dermatitis contact
Skin and subcutaneous tissue disorders
MedDRA (19.0)
Systematic Assessment
EG0001 affected33 at risk
EG0010 affected29 at risk
EG0020 affected43 at risk
EG003
Eczema
Skin and subcutaneous tissue disorders
MedDRA (19.0)
Systematic Assessment
EG0003 affected33 at risk
EG0012 affected29 at risk
EG0022 affected43 at risk
EG003
Hyperkeratosis
Skin and subcutaneous tissue disorders
MedDRA (19.0)
Systematic Assessment
EG0002 affected33 at risk
EG0010 affected29 at risk
EG0020 affected43 at risk
EG003
Pigmentation disorder
Skin and subcutaneous tissue disorders
MedDRA (19.0)
Systematic Assessment
EG0002 affected33 at risk
EG0012 affected29 at risk
EG0021 affected43 at risk
EG003
Pruritus
Skin and subcutaneous tissue disorders
MedDRA (19.0)
Systematic Assessment
EG0001 affected33 at risk
EG0010 affected29 at risk
EG0022 affected43 at risk
EG003
Urticaria
Skin and subcutaneous tissue disorders
MedDRA (19.0)
Systematic Assessment
EG0000 affected33 at risk
EG0010 affected29 at risk
EG0023 affected43 at risk
EG003
Hypertension
Vascular disorders
MedDRA (19.0)
Systematic Assessment
EG0001 affected33 at risk
EG0011 affected29 at risk
EG0023 affected43 at risk
EG003
Certain Agreements
Are all PI(s) employees of the sponsor?
No
Restriction Type
OTHER
Results Disclosure Restriction on PI(s)?
Yes
Other Details
Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.
Point of Contact
Title
Organization
Phone
Extension
Email
Study Director
Novartis Pharmaceuticals
862-778-8300
Novartis.email@novartis.com
ID
Term
D020529
Multiple Sclerosis, Relapsing-Remitting
D009103
Multiple Sclerosis
Ancestor Terms
ID
Term
D020278
Demyelinating Autoimmune Diseases, CNS
D020274
Autoimmune Diseases of the Nervous System
D009422
Nervous System Diseases
D003711
Demyelinating Diseases
D001327
Autoimmune Diseases
D007154
Immune System Diseases
Browse Leaves
Not provided
Browse Branches
Not provided
ID
Term
C578989
siponimod
Ancestor Terms
Not provided
Browse Leaves
Not provided
Browse Branches
Not provided
1 subjects
1 subjects
0 subjects
1 subjects
5 subjects
9 subjects
3 subjects
2 subjects
2 subjects
35.2
± 9.10
BG00437.2± 8.42
BG00535.7± 8.59
32
BG00318
BG00441
BG005130
Male
BG00012
BG00111
BG00211
BG00311
BG0049
BG00554
± 1.278
BG0021.95± 1.096
BG0031.88± 1.374
BG0042.22± 1.258
BG0052.07± 1.190
29
OG00450
6
OG0048
Other adverse events
Title
Measurements
OG00030
OG00126
OG00242
OG00329
OG00442
OG004
BAF312 .25 mg/2 mg
.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase
Units
Counts
Participants
OG00033
OG00129
OG00239
OG00329
OG00433
Title
Denominators
Categories
Conduction-Prolonged QTc
Title
Measurements
OG0005
OG0012
OG0025
OG0032
OG0044
Conduction - IVCD
Title
Measurements
OG0003
OG0018
OG0021
OG003
Conduction - AV Mobitz I
Title
Measurements
OG0001
OG0010
OG0020
OG003
Con:1st degree AV block
Title
Measurements
OG0000
OG0011
OG0021
OG003
Conduction - WPW
Title
Measurements
OG0000
OG0010
OG0020
OG003
4
Title
Denominators
Categories
Title
Measurements
OG0004
.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase
Units
Counts
Participants
OG00033
OG00129
OG00243
OG00329
OG00450
Title
Denominators
Categories
SBP Low: ≤ 90
Title
Measurements
OG0001
OG0013
OG0022
OG0031
OG0041
SBP ≥ 20 decrease from baseline
Title
Measurements
OG0008
OG00110
OG0024
OG003
SBP High: ≥ 160
Title
Measurements
OG0001
OG0011
OG0021
OG003
SBP ≥ 20 increase from baseline
Title
Measurements
OG0009
OG0018
OG00212
OG003
DBP Low: ≤ 50
Title
Measurements
OG0001
OG0010
OG0021
OG003
DBP ≥ 15 decrease from baseline
Title
Measurements
OG00014
OG0018
OG00210
OG003
DBP High: ≥ 100
Title
Measurements
OG0004
OG0017
OG0024
OG003
DBP ≥ 15 increase from baseline
Title
Measurements
OG0009
OG00113
OG00213
OG003
OG004
BAF312 .25 mg/2 mg
.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase
Units
Counts
Participants
OG00033
OG00129
OG00243
OG00329
OG00450
Title
Denominators
Categories
Oral herpes
Title
Measurements
OG0005
OG0010
OG0024
OG0032
OG0044
Herpes zoster
Title
Measurements
OG0005
OG0010
OG0023
OG003
Influenza
Title
Measurements
OG0003
OG0014
OG0023
OG003
Units
Counts
Participants
OG00033
OG00129
OG00243
OG00329
OG00450
Title
Denominators
Categories
Title
Measurements
OG0001
OG0010
OG0021
OG0030
OG0041
.5 mg dose in Double Blind Phase and 2 mg in Open Label Phase
OG004
BAF312 .25 mg/2 mg
.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase
Units
Counts
Participants
OG00033
OG00129
OG00243
OG00329
OG00450
Title
Denominators
Categories
Title
Measurements
OG0000.18(0.11 to 0.31)
OG0010.15(0.08 to 0.26)
OG0020.16(0.10 to 0.26)
OG0030.19(0.11 to 0.33)
OG0040.22(0.14 to 0.35)
BAF312 .5 mg/2 mg
.5 mg dose in Double Blind Phase and 2 mg in Open Label Phase
OG004
BAF312 .25 mg/2 mg
.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase
Units
Counts
Participants
OG00031
OG00126
OG00243
OG00329
OG00447
Title
Denominators
Categories
Free of Gd-enhanced T1 lesions at any scan
Title
Measurements
OG00058.1
OG00157.7
OG00258.1
OG00344.8
OG00466.0
Free of new/enlarging T2 lesions at any scan
Title
Measurements
OG00032.3
OG00142.3
OG00246.5
OG003
Free of Gd-enhanced T1 and new enlarged T2 lesions
Title
Measurements
OG00032.3
OG00142.3
OG00244.2
OG003
OG004
BAF312 .25 mg/2 mg
.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase